The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 11)
Improved Neuromodulation Approaches, 2014
Currently deep brain stimulation (DBS) is limited to "open-loop" stimulation, without real-time adjustment to the patient's state of activity, fluctuations and types of motor symptoms, medication dosages or neural markers of the disease. Changes to DBS settings only occur during clinical appointments or within small ranges by the patient at home. These limitations may contribute to...
Researchers: Helen Brontë-Stewart, MD, MSE
MJFF Research Grant, 2012
Promising Outcomes of Original Grant:
Excessive amounts of amyloid in brain tissue are believed to be toxic and cause the neuronal damage that results in dementia. Amyloid deposits can be detected in life using brain scans with the agent PiB. Using PiB brain scans, we found that ~30% of non-demented PD patients have increased amyloid deposits, and that high PiB uptake was associated with declines...
Researchers: John Growdon, PhD
Target Validation, 2010
Targeting the Unfolded Protein Response (UPR) Transcription Factor XBP-1 to Treat Parkinson's Disease
Our general objective is to investigate the role of a specific component of a cellular stress responses linked to organelle damage, the Unfolded Protein Response (UPR), in the development of Parkinson's disease. We intend to define the possible therapeutic benefits of alleviating cellular stress using gene therapy strategies in a disease context in vivo.
Project Description: ...
Researchers: Claudio Hetz Flores, PhD
MJFF Research Grant, 2010
Validation of enzymatic activity and neuropathology in G2019S LRRK2-induced dopaminergic neurodegeneration in a pre-clinical model of Parkinson's disease
Mutations in the LRRK2 gene are a common cause of familial and sporadic Parkinson’s disease. Familial LRRK2 mutations induce neuronal toxicity in vitro. Reliable pre-clinical models of LRRK2-induced neurodegeneration do not currently exist. We have recently developed a pre-clinical model of G2019S mutant LRRK2-induced dopaminergic neurodegeneration by viral-mediated gene tran...
Target Validation, 2009
Phosphorylation of alpha-synuclein at serine 129 is characteristic of Parkinson's disease (PD) and related alpha-synulceinopathies. Unraveling the role of phosphorylation in modulating the physiological and pathogenic activities of alpha-syn requires identification of the kinases and phosphatases involved in regulating its phosphorylation in vivo. Studies from our laboratory d...